1 citations
,
January 2023 in “Indian Journal of Dermatology/Indian journal of dermatology” 5% minoxidil can significantly increase hair growth in TRPS patients.
February 2020 in “DOAJ (DOAJ: Directory of Open Access Journals)” Minoxidil 0.25 mg with spironolactone 25 mg reduces hair loss and improves hair density in women.
25 citations
,
September 2018 in “Scientific Reports” Morroniside may help hair grow and stay in its growth phase by affecting certain cell signals.
January 2006 in “Zhongguo yaofang” The market for these drugs is expected to grow.
November 2025 in “Open Repository of the University of Porto (University of Porto)” Minoxidil and spironolactone can improve hair growth, but responses vary and side effects are common.
June 2026 in “EP Europace” Minoxidil and finasteride for hair loss may cause different types of heart rhythm issues.
14 citations
,
January 2020 in “Archivio Italiano di Urologia e Andrologia” Finasteride helps with prostate symptoms but may cause sexual side effects.
12 citations
,
March 2023 in “The FASEB Journal” Platelet-rich plasma can improve erectile function in older individuals by reducing prostate enlargement.
Restolin Hair Supplement may help hair growth but lacks FDA approval and clinical trial evidence.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
17 citations
,
May 1975 in “Clinical Pharmacology & Therapeutics” 306 citations
,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
14 citations
,
April 2009 in “Acta Medica Scandinavica” Minoxidil helps control blood pressure but has side-effects, so it's not for everyone.
February 2026 in “Journal of Cosmetic Dermatology” SEREVELLE safely and effectively promotes hair growth in adults with thinning hair.
January 2025 in “Annals of Maxillofacial Surgery” PRP therapy is more effective and preferred over minoxidil for hair loss.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
October 2022 in “The Journal of Clinical Pharmacology” Men with early-onset hair loss have less cardiometabolic benefit from bromocriptine.
March 2025 in “Authorea (Authorea)” PRP injections for hair growth can cause temporary vision loss, which may be resolved with treatment.
4 citations
,
May 2024 in “Rapid Communications in Mass Spectrometry” Girard's reagent P improves detection of spironolactone and its metabolites.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
October 2022 in “Biomolecules” Allopregnanolone can reduce gut inflammation and normalize neurotransmitter levels after finasteride withdrawal.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
July 2023 in “World Journal of Biology Pharmacy and Health Sciences” Trazodone and Chlorpromazine might help treat sexual dysfunction from finasteride and SSRIs.
31 citations
,
November 2014 in “Investigative Ophthalmology & Visual Science” A natural steroid in the body may protect against eye damage in glaucoma.
Finasteride can help regrow hair in male pattern baldness.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.